Challenges facing the Drug Discovery pipeline for Non-tuberculous mycobacteria.

Challenges facing the Drug Discovery pipeline for Non-tuberculous mycobacteria.
J Med Microbiol. 2015 Oct 29;
Authors: Soni I, De Groote MA, Dasgupta A, Chopra S
Abstract
Non tuberculous mycobacterial (NTM) infections are increasingly being reported worldwide. It is a major concern for healthcare professionals due to the multiple reasons ranging from the intrinsic resistance of NTM to most conventionally utilized antimicrobials to inharmonious diagnostic criteria utilized for evaluation of NTM infected patients, leading to high morbidity. In this review, we have highlighted the paucity of drugs having potent anti-NTM activity amongst the new antimicrobials currently under various stages of development for anti-tubercular activity and begs a call for the establishment of a concerted dedicated drug discovery pipeline targeting NTM's.
PMID: 26515915 [PubMed - as supplied by publisher]

Source: Journal of Medical Microbiology - October 29, 2015 Category: Microbiology Authors: Soni I, De Groote MA, Dasgupta A, Chopra S Tags: J Med Microbiol Source Type: research